Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NurOwn Phase 3 in ALS
NCT03280056Phase 3Completed
- Sponsor
- BrainStorm Cell Therapeutics Inc.
- Start
- Aug 2017
- Primary completion
- Sep 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of MSC-NTF in amyotrophic lateral sclerosis (ALS), sponsored by BrainStorm Cell Therapeutics Inc.. Started Aug 2017; status: completed.
02
Drugs
MSC-NTF
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03280056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03280056.